237 related articles for article (PubMed ID: 30587545)
1. SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
Wasserman I; Lee LH; Ogino S; Marco MR; Wu C; Chen X; Datta J; Sadot E; Szeglin B; Guillem JG; Paty PB; Weiser MR; Nash GM; Saltz L; Barlas A; Manova-Todorova K; Uppada SPB; Elghouayel AE; Ntiamoah P; Glickman JN; Hamada T; Kosumi K; Inamura K; Chan AT; Nishihara R; Cercek A; Ganesh K; Kemeny NE; Dhawan P; Yaeger R; Sawyers CL; Garcia-Aguilar J; Giannakis M; Shia J; Smith JJ
Clin Cancer Res; 2019 Mar; 25(6):1948-1956. PubMed ID: 30587545
[TBL] [Abstract][Full Text] [Related]
2. Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
Lee DW; Han SW; Bae JM; Jang H; Han H; Kim H; Bang D; Jeong SY; Park KJ; Kang GH; Kim TY
Clin Cancer Res; 2019 Oct; 25(20):6141-6147. PubMed ID: 31285374
[TBL] [Abstract][Full Text] [Related]
3. Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
BMC Cancer; 2019 May; 19(1):421. PubMed ID: 31060539
[TBL] [Abstract][Full Text] [Related]
4. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Zhang B; Zhang B; Chen X; Bae S; Singh K; Washington MK; Datta PK
Br J Cancer; 2014 Feb; 110(4):946-57. PubMed ID: 24384683
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
Dost Gunay FS; Kırmızı BA; Ensari A; İcli F; Akbulut H
Clin Colorectal Cancer; 2019 Jun; 18(2):e244-e250. PubMed ID: 30670344
[TBL] [Abstract][Full Text] [Related]
6. Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Hase K; Yamamoto J; Ueno H
Dis Colon Rectum; 2019 Nov; 62(11):1316-1325. PubMed ID: 31567925
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
[TBL] [Abstract][Full Text] [Related]
9. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
[TBL] [Abstract][Full Text] [Related]
10. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
[TBL] [Abstract][Full Text] [Related]
12. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
[TBL] [Abstract][Full Text] [Related]
13. Dynamic evaluation of mesenchymal circulating tumor cells in patients with colorectal cancer: Clinical associations and prognostic value.
Shi DD; Yang CG; Han S; Wang SY; Xiong B
Oncol Rep; 2020 Aug; 44(2):757-767. PubMed ID: 32627039
[TBL] [Abstract][Full Text] [Related]
14. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
15. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
[TBL] [Abstract][Full Text] [Related]
17. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
[TBL] [Abstract][Full Text] [Related]
18. Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer.
Kwon MJ
Arch Pharm Res; 2019 Nov; 42(11):947-961. PubMed ID: 31707598
[TBL] [Abstract][Full Text] [Related]
19. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
20. Whole-Slide Image Analysis Reveals Quantitative Landscape of Tumor-Immune Microenvironment in Colorectal Cancers.
Yoo SY; Park HE; Kim JH; Wen X; Jeong S; Cho NY; Gwon HG; Kim K; Lee HS; Jeong SY; Park KJ; Han SW; Kim TY; Bae JM; Kang GH
Clin Cancer Res; 2020 Feb; 26(4):870-881. PubMed ID: 31757879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]